Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-Induced Adverse Ocular Events-Incidence, Etiology, and Management.

Mickevicius, Tomas; Pink, Andrew E; Bhogal, Maninder; O'Brart, David; Robbie, Scott J

Mickevicius, Tomas; Pink, Andrew E; Bhogal, Maninder; O'Brart, David; Robbie, Scott J.

Afiliación

Mickevicius T; Department of Ophthalmology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Pink AE; Department of Ophthalmology, Hospital of Lithuanian University of Health Sciences, Kaunas, Lithuania; and.
Bhogal M; St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
O'Brart D; Department of Ophthalmology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Robbie SJ; Department of Ophthalmology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

Cornea ; 42(4): 507-519, 2023 Apr 01.

Article en En | MEDLINE | ID: mdl-36525340

Asunto(s)

Anticuerpos Monoclonales; Conjuntivitis; Humanos; Incidencia; Anticuerpos Monoclonales/efectos adversos; Conjuntivitis/inducido químicamente; Soluciones Oftálmicas/efectos adversos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Conjuntivitis / Anticuerpos Monoclonales Tipo de estudio: Etiology_studies / Guideline / Incidence_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Cornea Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google